Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UFT Adjuvant Chemotherapy vs Surgery Alone in Dukes C Colorectal Cancer
NCT00152230Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 1996
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur + uracil in colorectal cancer (CRC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Relapse-free survival at 5 years and Overall survival at 5 years. Started Oct 1996; status: completed.
02
Drugs
tegafur + uracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00152230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152230.